| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.05.23 | Britvic - Resilient performance | 538 | Edison Investment Research | Britvic's H1 results have demonstrated the business's resilience, with growth in underlying revenue and EBIT margin, and only a modest volume decline during H1. Britvic has continued to execute pricing... ► Artikel lesen | |
| 16.05.23 | Biodexa Pharmaceuticals - Pivoting out of a challenging FY22 | 471 | Edison Investment Research | Biodexa has reported its FY22 preliminary results and revised business strategy for the medium term. Funding challenges and slower traction than anticipated with the clinical pipeline during the period... ► Artikel lesen | |
| 16.05.23 | Newron Pharmaceuticals - Encouraging efficacy data from evenamide trial | 709 | Edison Investment Research | Newron has presented new efficacy data from its Phase II evenamide trial (study 014/015) at the CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International... ► Artikel lesen | |
| 16.05.23 | Kendrion - Q123 - good revenue growth at lower margins | 396 | Edison Investment Research | Kendrion's Q123 results were mixed with good revenue growth of 5% but an unexpected decline in EBITDA of 7%. Gross margin was under pressure due to Kendrion passing on material price inflation at no... ► Artikel lesen | |
| 16.05.23 | CentralNic Group - Cash allocated to deliver on objectives | 361 | Edison Investment Research | CentralNic's Q123 results showed robust revenue and profit growth, as well as a further deleveraging of its balance sheet. Its product comparison business VGL's entry into France provides a strong organic... ► Artikel lesen | |
| 16.05.23 | AVAX - Building on strong foundations | 345 | Edison Investment Research | AVAX is a leader in Greek construction, operating critical assets with long-term and visible cashflow streams, particularly in concessions. Greek economic growth should be stimulated to 2026 by the... ► Artikel lesen | |
| 16.05.23 | e-therapeutics - Enhancing siRNA drug discovery with LLMs | 417 | Edison Investment Research | e-therapeutics is a biotech leveraging its validated computational biology platform to identify novel, liver-associated targets and expand its internal pipeline of short interfering RNA (siRNA or RNAi)... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 336 |
| EVOTEC | 305 |
| TUI | 224 |
| NVIDIA | 185 |
| DEUTSCHE BANK | 181 |
| BAYER | 164 |
| PLUG POWER | 148 |
| NEL | 140 |
| RHEINMETALL | 137 |
| SIEMENS ENERGY | 119 |
| BARRICK GOLD | 112 |
| COMMERZBANK | 110 |
| BASF | 108 |
| TESLA | 107 |
| VOLKSWAGEN | 98 |
| RWE | 95 |
| BYD | 93 |
| DEUTSCHE LUFTHANSA | 89 |
| ALLIANZ | 87 |
| MERCEDES-BENZ | 83 |
| DEUTSCHE TELEKOM | 82 |
| RENK GROUP | 81 |
| HEIDELBERGER DRUCK | 79 |
| E.ON | 76 |
| AIXTRON SE | 75 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
